
## PHARMING GROUP N.V.

ISIN: NL0010391025 WKN: 518940 Asset Class: Stock



### **Company Profile**

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.

## Financial figures, Fiscal year: from 01.01. to 31.12.

	20	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity	
Current assets	286,373,000		260,014,000		219,349,000		
Common stock capital		6,942,000		7,035,000		6,532,000	
Fixed assets	139,966,000		144,797,000		135,138,000		
Equity capital of a company		198,054,000		191,743,000		169,641,000	
Cash and cash equivalents	55,891,000		194,476,000		168,968,000		
Accrued liabilities		0		0		0	
Other assets	-		-		-		
Current liabilities		70,581,000		55,936,000		41,128,000	
Prepayments and accrued income	-		-		-		
Non-current liabilities		157,703,000		157,131,000		143,718,000	
Different income		-		-		-	
Other liabilities		0		0		145,000	
Total assets	426,339,000	426,339,000	404,811,000	404,811,000	354,488,000	354,488,000	

#### **Balance notes**

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	-	-	-
Equity ratio	46.45%	47.37%	47.86%
Debt-equity ratio	115.26%	111.12%	108.96%

## **Others**

	2023	2022	2021
Tax Expense Rate	12.49%	8.17%	31.64%

# PHARMING GROUP N.V.

ISIN: NL0010391025 WKN: 518940 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	226,910,000	195,648,000	168,252,000
Net income	-9,756,000	13,010,000	13,533,000
EBIT	-8,591,126	20,407,730	24,125,601
Operating income before taxes	-10,843,000	15,290,000	18,937,000
Cash Flow	-19,546,000	17,348,000	27,857,000
Net interest income	-2,252,000	-5,117,000	-5,187,000
Research and development expenses	60,144,000	48,458,000	56,868,000
Income taxes	-1,354,000	1,249,000	5,991,000
Result from investments in subsidaries, associates and other	-267,000	-1,030,000	587,000
Revenues per employee	-	-	-

<b>Board of Directors</b>	
Richard Peters	Chairman of Supervisory Board
Jabine T. M. van der Meijs	Member of Supervisory Board
Mark Pykett	Member of Supervisory Board
Barbara Yanni	Member of Supervisory Board
Deborah Jorn	Member of Supervisory Board
Leonard Kruimer	Member of Supervisory Board
Steven Baert	Member of Supervisory Board

Members of Management Board			
Sijmen de Vries	Chairman of Managing Board		
Anurag Relan	Member of Executive Committee		
Jeroen Wakkerman	Member of Executive Committee		
Mireille Sanders	Member of Executive Committee		
Ruud van Outersterp	Member of Executive Committee		
Stephen Toor	Member of Executive Committee		